In a patient cohort with stage IV cancer patients, all six patients (bladder cancer, breast cancer, endometrial stromal sarcoma, lung adenocarcinoma, squamous cell carcinoma of the hypopharynx) with MDM2 amplification showed a time-to-treatment failure of under two months. Here, MDM2 is linked to breast carcinoma.